Core B, the Biostatistics and Research Informatics Core (BRIC) of the City of Hope Lymphoma SPORE, provides statistical expertise across all SPORE research activities, including study design, safety monitoring, data collection, data quality assurance, data analysis, and multi-center study site coordination. BRIC will ensure that the proposed research hypotheses will be addressed with appropriate measures, tests, and interpretation, whether the data come from epidemiological studies, basic science, translational, immunologic studies, imaging, or clinical trials. The centralized, comprehensive framework of BRIC assures each SPORE investigator access to statistical experts who have appropriate experience, interests and time to engage in the collaborative development of study designs, analysis plans, data analysis, interpretation, and abstract /manuscript preparation. The BRIC will also provide infrastructure for the management and integration of both existing and newly collected data through consistent and compatible data handling. The Core plays an integral role in the scientific development, execution, and analysis of ail projects in the SPORE, including the clinical trials Core investigators have extensive experience in quantitative methods for biomedical applications, including clinical, basic, and translational science studies, particularly in hematologic malignancies. BRIC is committed to collaboration, to help ensure the scientific integrity of the SPORE investigations, by participating in regular project and program meetings, and providing rigorous and innovative input on all statistical and information management matters arising within the projects.
The specific aims of BRIC are as follows:
Specific Aim 1. To support high quality data management through state-of-the-art information technologies, ensuring standardization, quality assurance, security, training, monitoring, and data integration, and multicenter coordination when appropriate.
Specific Aim 2. To provide biostatistical support to the Projects, Cores and Programs, by consulting on the design, data monitoring, analysis, statistical modeling, visualization, interpretation and publication of the data generated by SPORE activities.
As a critical shared resource of the Lymphoma SPORE, the purpose of the Biostatistics and Research Informatics Core (BRIC) is to provide the essential information management, quality assurance, experimental design, and biostatistical analysis resources required to conduct the ongoing and planned investigations of lymphoid malignancies.
|Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520|
|Budde, Lihua E; Wu, David; Martin, Daniel B et al. (2018) Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 183:601-607|
|Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730|
|Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707|
|Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60|
|Herrera, Alex F; Moskowitz, Alison J; Bartlett, Nancy L et al. (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183-1194|
|Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87|
|Wang, Xiuli; Walter, Miriam; Urak, Ryan et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 24:106-119|
|Mei, Matthew G; Cao, Thai M; Chen, Lu et al. (2017) Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant 23:1861-1869|
|Herrera, Alex F; Mei, Matthew; Low, Lawrence et al. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 35:24-31|
Showing the most recent 10 out of 97 publications